ZOMETA® – Helps Patients with Multiple Myeloma and Skeletal-Related Events from bone metastases
ZOMETA - Zoledronic AcidZOMETA - Zoledronic Acid Novartis Oncology
HomeZOMETA - International SiteZOMETA - US ResidentsZOMETA - Country Sites
ZOMETA - English ZOMETA - Deutsch ZOMETA - Espanol ZOMETA - Francais ZOMETA - Italiano

Left Nav Search
ZOMETA-Videos
Blue Arrow View videos on bone
metastases and the ZOMETA
mechanism of action

Learn more about the ZOMETA(zoledronic acid) mechanism of action

 
ZOMETA European Summary of Product Characteristics
Blue Arrow For non-U.S. Healthcare Professionals: Get information about ZOMETA and its product characteristics

Learn more about ZOMETA product characteristics 		 
About ZOMETA: defend against SREs across a broad range of tumour types



ZOMETA® effectively helps to protect patients with multiple myeloma from the threat of SREs

Time to first SRE, ZOMETA vs placebo in patients with multiple myeloma6

  • ZOMETA delivered equivalent efficacy to that of pamidronate in delaying SREs (376 days vs 356 days, respectively) for patients with multiple myeloma or breast cancer in a noninferiority trial6

ZOMETA can delay and reduce SREs in patients with multiple myeloma and bone lesions6
 

Disclaimer: This is an international website for ZOMETA® (zoledronic acid) and is intended for healthcare professionals outside the US. If you are a US resident, please click on the US Residents link at the top of this page. The information on this site is not country-specific and may contain information that is outside the approved indications in the country in which you are located.

About ZOMETA | ZOMETA Patient Case Studies | ZOMETA Dosing & Administration | ZOMETA Safety & Tolerability | ZOMETA Clinical News | ZOMETA For Your Patients | Professional Resource Center
ZOMETA Around the World

About Novartis OncologyZometa Site MapZometa ContactZOMETA Privacy
 


Use of this website is subject to our Terms of Use
© 2010 Novartis AG.